Lewis K. Antwi

FDA investigator

Appears on 11 documents from 2019 to 2025, most often at sites in Pennsylvania. Most often cites production record review (21 CFR 211.192).

11
Documents on file
2.6
Observations per 483
2019
First seen
2025
Most recent

What they cite most

From 26 observations

Activity by year

2019: 1, 2022: 4, 2023: 1, 2024: 3, 2025: 2

Where

Pennsylvania 2 · California 1 · Indiana 1 · Italy 1 · Massachusetts 1 · New Hampshire 1

Is Lewis K. Antwi coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

11 documents, newest first
FirmOpen
483 FDA Form 483 Krystal Biotech Inc., Pittsburgh, PA Jan 2025Jan 30, 2025 · Pittsburgh, Pennsylvania
483 Krystal Biotech, Inc.Jan 30, 2025 · Pittsburgh, Pennsylvania
483 Wyeth Farma SANov 22, 2024 · San Sebastian de los Reyes, Spain
483 FinVector OyMay 28, 2024
483 Lonza Houston Inc.Mar 7, 2024 · Portsmouth, New Hampshire
483 Brammer Bio MA, LLCAug 30, 2023 · Cambridge, Massachusetts
483 Wyeth Pharmaceutical Division of Wyeth Holdings LLCNov 18, 2022 · Sanford, North Carolina

About this profile

What does Lewis K. Antwi inspect?

Lewis K. Antwi appears on 11 documents on file covering 10 sites, most often in Pennsylvania.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.160 and 21 CFR 211.84.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Lewis K. Antwi is dated Jan 30, 2025.